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1  |  INTRODUC TION
Guidelines are available for transplantation of all solid organs but the 
pancreas and the intestine.1– 13 Unfortunately, pancreas transplan-
tation is a relatively low volume but high complexity procedure that 
has never gained widespread acceptance. For instance, many of the 
medical protocols used in pancreas transplantation are borrowed 
from other types of transplantation, mostly from the kidney, and all 
immunosuppressive drugs are used off- label in pancreas transplanta-
tion.14 In addition, because most pancreas transplants are performed 
as either simultaneous pancreas- kidney (SPK) or pancreas after kid-
ney (PAK) transplants, the majority of recipients suffer from advanced 
diabetic nephropathy, a condition that has been associated with an 
increase in all- cause mortality due to higher incidence of micro- and 
macrovascular complications of diabetes.15 Few patients are referred 
for pancreas transplant alone (PTA) at a stage when extrarenal diabetic 
complications might be reversible. Although many uremic patients can 
still receive a pancreas transplant in conjunction with a kidney trans-
plant, the high prevalence and severity of associated chronic complica-
tions of diabetes cause these recipients to be less likely to experience 
stabilization or reversal of progressive diabetic complications.16,17
In recent years, there has been a decline in the number of pancreas 
transplants in the United States, Europe, and the United Kingdom.18– 20 
Although the reasons for this decline are multifactorial, the lack of 
objective assessment of the impact of pancreas transplantation on 
the treatment of diabetic patients and absence of validated practice 
guidelines may be among the contributing factors. In selected patients, 
pancreas transplantation provides dramatic improvements in quality of 
life21– 35 and may prolong survival.33– 39 Additionally, some traditional 
deterrents have been minimized because pancreas transplantation 
currently requires the same immunosuppression as kidney transplan-
tation40 and surgical complications are observed at lower rates.41
We report herein the expert recommendations for the prac-
tice of pancreas transplantation developed during the First World 
Consensus Conference on Pancreas Transplantation held in Pisa, 
Italy, on October 17– 19, 2019. We also report several additional 
deliberations on the impact of the different types of pancreas 
transplantation on the course of diabetes that were crafted by an 
independent jury following an exhaustive review and presentation 
of data from the literature and audience discussions with experts.
2  |  SUMMARY OF METHODS
The methods used to achieve the consensus were presented in detail 
in a dedicated manuscript.42
Briefly, the steering committee defined 144 questions (grouped in 12 
topics). The 12 topics were categorized into two key domains. The first do-
main (three topics— 35 questions) included “nontechnical” issues related 
to the impact of SPK transplant, PAK transplant, and PTA on the man-
agement of patients with diabetes. The second domain (nine topics— 109 
questions) dealt with technical issues related to the practice of pancreas 
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The First World Consensus Conference on Pancreas Transplantation provided 49 jury de-
liberations regarding the impact of pancreas transplantation on the treatment of diabetic 
patients, and 110 experts’ recommendations for the practice of pancreas transplantation. 
The main message from this consensus conference is that both simultaneous pancreas- 
kidney transplantation (SPK) and pancreas transplantation alone can improve long- term 
patient survival, and all types of pancreas transplantation dramatically improve the quality 
of life of recipients. Pancreas transplantation may also improve the course of chronic com-
plications of diabetes, depending on their severity. Therefore, the advantages of pancreas 
transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney 
transplantation increases the risk of mortality only in the early period after transplanta-
tion, but is associated with improved life expectancy thereafter. Additionally, preemptive 
SPK, when compared to SPK performed in patients undergoing dialysis, appears to be as-
sociated with improved outcomes. Time on dialysis has negative prognostic implications in 
SPK recipients. Increased long- term survival, improvement in the course of diabetic com-
plications, and amelioration of quality of life justify preferential allocation of kidney grafts 
to SPK recipients. Audience discussions and live voting are available online at the follow-
ing URL address: http://media eventi.unipi.it/categ ory/1st- world - conse nsus- confe rence -  
of- pancr eas- trans plant ation/ 246.
K E Y W O R D S
clinical research/practice, diabetes, pancreas/simultaneous pancreas- kidney transplantation, 
survey
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transplantation. A systematic literature review was conducted according 
to the Cochrane Handbook for Systematic Reviews of Interventions for 
each topic and was reported according to the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses (PRISMA).43,44 Quality of ev-
idence was assessed using the SIGN (Scottish Intercollegiate Guidelines 
Network) methodology.45 Questions in the first domain were assessed 
using the Zurich- Danish model46 that charges an independent jury to 
draw the final deliberations. Questions in the second domain were as-
sessed and approved by a panel of experts in pancreas transplantation 
and were validated by a distinct group of experts using the AGREE II 
instrument (Appraisal of Guidelines for Research and Evaluation II).47 
Jury deliberations and expert recommendations received a GRADE 
rating (Grading of Recommendations, Assessment, Development and 
Evaluations).48 Consensus (agreement rate ≥85%) was reached by two 
online Delphi rounds and was finalized, after on- site discussions and live 
voting (Pisa, Italy, October 18 and 19, 2019).
Audience discussions and live voting are available online at the 
following URL address: http://media eventi.unipi.it/categ ory/1st- 
world - conse nsus- confe rence - of- pancr eas- trans plant ation/ 246
3  |  DEFINITIONS
Sensitization (or sensitized patient) was defined as the presence of 
circulating antibodies directed against human leukocyte antigens 
(HLA).49 High sensitization (or highly sensitized patients), was de-
fined as a panel reactive antibody (PRA) >85%.50
Obesity was defined according to World Health Organization (i.e., 
body mass index [BMI] ≥30 kg/m2).51 Obesity classes (i.e., class I, class 
II, and class III) and ethnic variations that affect obesity definition were 
not considered due to lack of granular data in available literature.
Preemptive SPK transplantation was defined as the combined 
transplantation of a pancreas and a kidney in patients with stage 4/5 
chronic kidney disease before they initiate dialysis.
4  |  RESULTS
4.1  |  Jury deliberations
The jury could not deliberate on two queries, due to lack of evi-
dence, and released 49 deliberations. No deliberation was graded 
1A. Twenty- three of 49 deliberations could not be graded. The re-
maining 26 deliberations were rated GRADE 2B (n = 22) and GRADE 
2C (n = 4) (Figure 1A).
Jury deliberations are reported in Tables 1- 3.
4.2  |  Experts’ recommendations
Experts released 110 recommendations. No recommendation was 
graded 1A. Fifty- one recommendations could not be graded. The 
remaining 59 recommendations were rated GRADE 1B (n = 13), 
GRADE 1C (n = 2), GRADE 2A (n = 2), GRADE 2B (N = 20), and 
GRADE 2C (n = 22) (Figure 1B).
Experts’ recommendations are reported in Tables 4- 12.
5  |  DISCUSSION
This world consensus conference provides the first practice guide-
lines for pancreas transplantation. Islet cell transplantation, which 
is a further therapeutic option for beta- cell replacement in selected 
diabetic patients, was intentionally not addressed. Some of the rec-
ommendations provided for pancreas transplantation might also 
apply to islet cell transplantation, but this was not the aim of this 
consensus conference and no commitment exists for their use in this 
setting.
This consensus conference provided 49 jury deliberations 
and 110 expert recommendations. It is interesting to note that 
no statement achieved GRADE 1A, as no meta- analysis of 
prospective and randomized trials exists on discussed issues. 
Approximately 40% of approved statements could not be graded 
while an additional 10% resulted in extremely weak recommen-
dations. This is probably the combined result of difficulties in de-
signing and conducting clinical studies in the setting of a rarely 
performed procedure, lack of interest from stakeholders, paucity 
of investments from pharmaceutical companies in clinical trials, 
and the long period in which surgeons had to achieve clinical 
success rather than scientific evidence. On practical grounds, in 
pancreas transplantation, there are still many issues for which 
practice is not strongly supported by evidence, despite excellent 
clinical results.21– 39
5.1  |  Jury deliberations— impact of SPK
The jury deliberated that SPK transplantation improves both quality 
of life and long- term survival of patients with insulin- dependent dia-
betes in comparison to current medical treatments and other trans-
plant options.33,34,37,38,52– 60 These deliberations were not based on 
a high level of evidence and applied more strictly to patients with 
type 1 diabetes. In patients with type 2 diabetes, it was not clear if 
SPK transplant conveyed a survival advantage over live donor renal 
transplantation alone, while it was deemed convenient over both di-
alysis and deceased donor kidney transplantation.
The association between SPK transplant and improved survival in 
type 1 diabetic recipients was reported several times.33,34,37,38,52– 59 
The acknowledgment of this advantage by an independent jury 
prompts the transplant community to further pursue SPK transplan-
tation, especially when a live kidney donor is not available.
The jury also provided deliberations regarding the value of SPK 
transplantation performed in preemptive recipients.61– 63 This is a 
key issue, considering donor shortage and the need to maintain a 
balance between equity and efficacy in graft allocation policy.64,65 
While preemptive SPK transplant seems to be an excellent option in 
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the individual patient, sound evidence is still missing to demonstrate 
if and to which extent preemptive SPK transplantation could be con-
venient in the average SPK transplant recipient.
5.2  |  Jury deliberations— impact of PAK
PAK was criticized due to possibly increased risks compared to con-
tinued insulin therapy. Indeed, in addition to the general concerns 
that apply to all types of pancreas transplantation, PAK transplant 
was associated with increased risk of renal graft loss.66,67
Jury deliberations indicate that PAK transplant increases the risk 
of mortality early after transplantation, but improves life expectancy 
thereafter. As already observed for the kidney,68 higher early mortality 
is the consequence of the need for a major surgical procedure and ad-
ministration of additional immunosuppression and should not discour-
age PAK transplantation. Indeed, after the early posttransplant period, 
the additional risk of mortality disappears while quality of life is greatly 
improved and renal graft function is better preserved. Considerations 
on quality of life and renal graft function apply well to patients with 
type 1 diabetes. In patient with type 2 diabetes, PAK transplant was 
deemed feasible but evidence on possible advantages was lacking.
F I G U R E  1  Level of evidence 
and strength of statements. (A) 
Jury deliberations; (B) expert 
recommendations.
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TA B L E  1  Impact of simultaneous pancreas- kidney (SPK) transplantation
Query Deliberation Grade
A.1 – “In suitable recipients, does an SPK transplant increase life 
expectancy or improve quality of life?”
1. SPK transplantation improves quality of life and long- term 
survival compared to current medical treatment for people 
on the waitlist and compared to other transplant options
2B
2. The survival advantage with SPK transplantation is greater 
when a live donor kidney is not available or suitable
2B
3. SPK transplantation improves quality of life and is not 
associated with an increased risk of premature loss of renal 
graft function
2B
A.2 – “In suitable SPK recipients with type 1 diabetes does an SPK 
transplant improve life- expectancy or quality of life?”
1. In type 1 diabetes, SPK transplantation improves quality of 
life and long- term survival compared to current medical 
treatment for people on the waitlist and compared to other 
transplant options
2B
2. The survival advantage with SPK transplantation is greater 
when a live donor kidney is not available or suitable
2B
3. SPK transplantation improves quality of life and is not 
associated with an increased risk of premature loss of renal 
graft function
2B
A.3 – “In suitable SPK recipients with type 2 diabetes, does an SPK 
transplant improve life- expectancy or quality of life?”
1. In suitable type 2 diabetes recipients, SPK transplantation 
improves quality of life and improves survival compared to 
patients remaining on dialysis
NG
2. In type 2 diabetes, SPK transplantation improves survival 
compared to deceased donor kidney transplantation alone
2B
3. In people with type 2 diabetes, there is insufficient evidence 
to determine whether survival is improved by SPK 
transplantation compared to living donor kidney transplant 
alone
NG
A.4 – “In patients with type 1 diabetes and end stage- renal disease on 
dialysis, does an SPK transplant increase longevity or improve quality 
of life?”
In patients with type 1 diabetes and end- stage renal disease 
on dialysis, SPK transplantation both improves quality of 
life and increases longevity compared to current medical 
therapies
2B
A.5 – “In patients with type 1 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant increase longevity or improve quality 
of life compared to live donor kidney transplantation?”
1. Live donor kidney transplantation alone is an alternative to 
SPK transplantation in case of anticipated long wait times 
and in people who do not qualify for dual transplantation
2C
2. Live donor kidney transplantation alone achieves survival 
similar to SPK transplantation in the medium term, but SPK 
transplantation has improved long- term survival
2C
A.6 – “In patients with type 1 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant increase longevity or improve quality 
of life compared to live donor kidney transplantation with islet cell 
transplantation?”
Because of lack of evidence, no conclusions can be drawn - 
A.7 – “In patients with type 1 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant increase longevity or improve quality 
of life compared to deceased donor kidney transplantation?”
In selected patients, SPK transplantation improves long- 
term survival, kidney graft function, and quality of life 
compared to patients who receive deceased donor kidney 
transplantation alone
2C
A.8 – “In patients with type 1 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant increase longevity or improve quality 
of life compared to deceased donor kidney transplantation with islet 
cell transplantation?”
Because of lack of evidence, no conclusions can be drawn - 
A.9 – “In preemptive SPK recipients with type 1 diabetes does an SPK 
transplant improve longevity or quality of life?”
There is indirect evidence that preemptive SPK 
transplantation improves longevity and quality of life in 
patients with type 1 diabetes
NG
A.10 – “In preemptive SPK recipients with type 1 diabetes does an SPK 
transplant improve longevity or quality of life compared to live donor 
kidney transplantation?”
Data are limited. Preemptive SPK transplantation and live 
donor kidney transplants both seem to provide excellent 
long- term outcomes in patients with type 1 diabetes
NG
(Continues)
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5.3  |  Jury deliberations— impact of PTA
Deliberations on PTA were truly important because they underscored 
the high value of this type of transplantation. Indeed, contrary to a 
landmark study,69 the jury deliberated that PTA does not increase the 
long- term risk of death compared with people remaining on the waiting 
list. PTA might be actually associated with a long- term survival advan-
tage in diabetic patients who have impaired hypoglycemia awareness. 
Although these deliberations are not based on new data,27,39,70,71 they 
are key since they are provided by an independent jury and unambigu-
ously debunk the myth of PTA recipients exposed to undue risks.
A further concern with PTA is the risk of accelerated loss of 
renal function.73– 75 The jury deliberated that impaired pretransplant 
renal function is a risk factor for accelerated end- stage renal fail-
ure after PTA, while an estimated glomerular filtration rate ≥60 ml/
min/1.73 m2 is sufficient to protect most recipients against this risk. 
The use of calcineurin inhibitors (CNIs) may contribute to a decline in 
renal function after PTA, while normalization of glucose levels could 
have beneficial effects on underlying diabetic nephropathy in the 
long term.76,77 These additional and important data underscore the 
key role of accurate recipient selection for safe PTA and appropriate 
management of immunosuppression. Probably, patients with hypo-
glycemia unawareness should be referred for PTA before develop-
ment of diabetic nephropathy.
The jury also deliberated that PTA improves quality of life, may 
stabilize/improve diabetic retinopathy (depending on severity of ini-
tial retinal damage), and may slow the progression of diabetic neu-
ropathy.32,78– 80 No conclusion could be drawn regarding the effects 
of PTA on progression of cardiovascular disease. The positive effect 
of PTA on the course of microvascular complications of diabetes is 
Query Deliberation Grade
A.11 – “In preemptive SPK recipients with type 1 diabetes does an SPK 
transplant improve longevity or quality of life compared to live donor 
kidney transplantation with islet cell transplantation?”
Because of lack of evidence, no conclusions can be drawn - 
A.12 – “In preemptive SPK recipients with type 1 diabetes does an SPK 
transplant improve longevity or quality of life compared to deceased 
donor kidney transplantation?”
Indirect evidence from deceased donor kidney transplant 
alone in patients with type 1 diabetes suggests that 
preemptive SPK transplantation is superior in terms of 
quality of life and longevity compared to deceased donor 
kidney transplantation alone
NG
A.13 – “In preemptive SPK recipients with type 1 diabetes does an SPK 
transplant improve longevity or quality of life compared to deceased 
donor kidney transplantation with islet cell transplantation?”
Because of lack of evidence, no conclusions can be drawn
A.14 – “In patients with type 2 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant improve quality of life or increase 
longevity?”
Indirect evidence from kidney transplant recipients with 
type 2 diabetes suggests that, in selected patients, SPK 
transplantantation could be associated with improved 
quality of life and increased longevity compared to 
remaining on dialysis
NG
A.15 – “In patients with type 2 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant improve quality of life or increase 
longevity compared to live donor kidney transplantation?”
There is limited evidence. Indirect evidence suggests that 
in selected patients with type 2 diabetes on dialysis, 
the sustained normoglycemia after successful SPK 
transplantation offers additional advantages compared to 
live donor kidney transplantation alone
NG
A.16 – “In patients with type 2 diabetes and end- stage renal disease on 
dialysis, does an SPK transplant improve quality of life or increase 
longevity compared to deceased donor kidney transplantation?”
There is limited evidence. Indirect evidence suggests that 
in selected patients with type 2 diabetes on dialysis, 
the sustained normoglycemia after successful SPK 
transplantation offers additional advantages compared to 
deceased kidney donor transplantation alone
NG
A.17 – “In preemptive recipients with type 2 diabetes does an SPK 
transplant improve quality of life or increase longevity compared to 
current medical therapy?”
There are limited data. Indirect evidence from type 1 diabetes 
suggests that in selected patients with type 2 diabetes, 
preemptive SPK transplant improve quality of life and 
increase longevity compared to current medical therapy
NG
A.18 – “In preemptive recipients with type 2 diabetes does an SPK 
transplant improve quality of life or increase longevity compared to 
live donor kidney transplantation?”
There are limited data. It is not known whether preemptive 
SPK transplantation improves quality of life or increases 
longevity compared to live donor kidney transplantation in 
type 2 diabetes
NG
A.19 – “In preemptive recipients with type 2 diabetes does an SPK 
transplant improve quality of life or increase longevity compared to 
deceased donor kidney transplantation?”
There are limited data. It is not known whether preemptive 
SPK transplantation improves quality of life or 
increases longevity compared to deceased kidney donor 
transplantation in type 2 diabetes
NG
Abbreviations: NG, not graded; SPK, simultaneous pancreas kidney.
TA B L E  1  (Continued)
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an important piece of information that sheds additional light on the 
role of PTA in the management of selected diabetic patients.
Overall, based on jury deliberations, PTA appears fully justified in 
patients with hypoglycemia unawareness and possibly in patients with 
other chronic complications of diabetes of mild/moderate severity. 
Regarding hypoglycemia unawareness, islet cell transplantation could be 
an alternative option, but this issue was not addressed in the consensus.
5.4  |  Expert panel recommendations— activity 
volume and innovation
5.4.1  |  Activity volume
For many surgical procedures, there is a clear relationship between 
volume of activity and outcomes.81 In transplantation, volume- 
outcome relationship has been shown for the kidney,82 liver,83 
heart,84 and lung.85
In the United States, approximately 70% of transplant cen-
ters are low volume. Low volume programs (one to six pancreas 
transplants per year) may be associated with worse outcomes.86 
Volume- outcome relationship was confirmed in Europe,16 by the 
Scientific Registry of Transplant Recipients,17 and in few stud-
ies.18,19 Based on these data, low volume seems to be associated 
with a higher risk for pancreas failure,86 but there is no study 
specifically addressing the issue of minimum annual volume of 
pancreas transplant per center. Therefore, and considering that 
outcomes after pancreas transplantation are multifactorial and 
not just determined by surgery and/or care in the immediate post-
transplant period, experts could not define a minimum annual vol-
ume but suggested that higher annual volume could be among the 
factors contributing to good outcomes.
No specific study addressed the impact of surgeon volume on 
outcomes of pancreas transplantation. As a consequence, no annual 
volume threshold exists. Evidence from other high complexity and 
relatively low volume procedures, such as pancreatoduodenectomy, 
suggests that higher volume surgeons perform better as compared to 
lower volume surgeons.87 Hospital volume can mitigate the impact of 
low volume surgeons on outcomes,88 and experienced surgeons have 
results similar to those achieved by high volume surgeons.89 Experts 
TA B L E  2  Impact of pancreas after kidney (PAK) transplantation
Query Deliberation Grade
B.1 – “In suitable PAK recipients, is PAK transplant 
associated with additional risks? What is the risk of 
death compared to current medical therapies?”
1. At 90 days, PAK transplantation is associated with an increased risk of 
mortality (compared to staying on the waitlist) which persists to 1 year
2B
2. After 1 year, PAK transplantation is associated with decreased mortality 2B
B.2 – “In suitable PAK recipients with type 1 diabetes, does 
PAK transplant prolong life or improve quality of life 
compared to current diabetes therapy?”
1. Available evidence in patients with type 1 diabetes cannot determine 
whether PAK transplantation prolongs life expectancy
2B
2. PAK transplantation clearly improves quality of life due to superior renal 
graft survival and improved metabolic control
2B
B.3 – “In suitable PAK recipients with type 1 diabetes 
who received a live donor kidney, does PAK transplant 
increase life expectancy or improve quality of life?”
1. Available evidence in patients with type 1 diabetes cannot determine 
whether PAK transplantation in live donor kidney recipients prolongs 
life expectancy
2B
2. PAK transplantation clearly improves quality of life due to superior renal 
graft survival and improves metabolic control compared to continued 
medical treatment of diabetes
2B
B.4 – “In suitable PAK recipients with type 1 diabetes 
who received a deceased kidney transplant, does PAK 
transplant increase life expectancy or improve quality 
of life?”
1. Available evidence in patients with type 1 diabetes cannot determine 
whether PAK transplantation in deceased kidney transplant recipients 
prolongs life expectancy
NG
2. PAK transplantation clearly improves quality of life due to superior renal 
graft survival and improves metabolic control compared to continued 
medical treatment of diabetes
NG
B.5 – “In suitable PAK recipients with type 2 diabetes does 
PAK transplant increase life expectancy or improve 
quality of life?”
Based on available evidence, PAK transplant in people with type 2 diabetes 
is feasible, but further data are required before conclusions on the 
impact of PAK transplant on life expectancy or quality of life can be 
made
NG
B.6 – “In suitable PAK recipients with type 2 diabetes does 
PAK transplant after a live donor kidney transplant 
increase life expectancy or improve quality of life?”
Based on available evidence, PAK transplant after a live donor kidney 
transplant in people with type 2 diabetes is feasible. Further data are 
required before conclusions on the impact on life expectancy or quality 
of life can be made
NG
B.7 – “In suitable PAK recipients with type 2 diabetes does 
PAK transplant after deceased donor kidney transplant 
increase life expectancy or improve quality of life?”
Based on available evidence, PAK transplant after a deceased donor kidney 
transplant in people with type 2 diabetes is feasible. Further data are 
required before conclusions on the impact on life expectancy or quality 
of life can be made
NG
Abbreviations: NG, not graded; PAK, pancreas after kidney.
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recommended that pancreas transplantation should not be performed 
occasionally by the individual surgeon and that younger surgeons should 
have received formal training and/or should operate under supervision.
5.4.2  |  Innovation
Regarding innovation, two issues were assessed: live donor segmen-
tal pancreas transplantation and robotic pancreas transplantation.
Live donor segmental pancreas transplantation has been per-
formed only in a few centers, for a total of approximately 200 pro-
cedures worldwide. Most of these transplants were done at a single 
institution, the University of Minnesota.90,91 In general, segmental 
live donor pancreas transplantation is an option in sensitized recip-
ients who have a suitable donor with a negative crossmatch. Due 
to the limited experience, donor risks cannot be precisely defined. 
Experience with the so called “Warshaw procedure,”92 correspond-
ing to a live donor segmental pancreatectomy performed in patients 
with benign or low- grade pancreatic tumors,93 shows that this pro-
cedure is quite safe.94 However, short- and long- term risks do exist. 
The most frequent early complications include splenic infarction 
(potentially requiring splenectomy), postoperative pancreatic fistula, 
and postoperative hemorrhage. Delayed complications/sequelae in-
clude gastric varices, hypersplenism, and diabetes. Sinistral portal 
hypertension was reported to have no clinical consequence in a large 
series of Warshaw procedures with long- term follow- up,94 but a live 
donor of a segmental pancreatic graft did present with an upper 
gastrointestinal hemorrhage 25 years after surgery.95 Splenectomy 
is curative in these patients, but massive gastrointestinal bleeding 
can be life- threatening. Therefore, experts recommended that live 
donor segmental pancreas transplantation could be carefully con-
sidered in sensitized recipients and in extremely well- selected pairs. 
They also recommended that the center be responsible to ensure 
quality of the procedure and careful lifelong follow- up of the donor.
The first robotic pancreas transplantation was performed in Pisa, 
Italy, on September 27, 2010 and the first three cases were reported 
TA B L E  3  Impact of pancreas transplantation alone (PTA)
Query Deliberation Grade
C.1 – “In suitable recipients is PTA associated with an 
increased risk of death when compared to current 
medical therapies?”
1. PTA is not associated with an increased long- term risk of death compared 
with people remaining on the waiting list
2B
2. Indirect evidence suggests that PTA could be associated with a long- term 
survival advantage compared to people who have diabetes and impaired 
hypoglycemia awareness
2B
C.2 – “In suitable PTA recipients, is PTA associated 
with an increased risk of earlier renal failure 
compared to current medical therapy?”
1. Renal failure has occurred in people receiving PTA who had significant 
pretransplant renal impairment
2B
2. Renal failure post- PTA is uncommon if pretransplant estimated glomerular 
filtration rate is ≥60 ml/min/1.73 m2
2B
3. In some people, there may be a decline in renal function after PTA with 
calcineurin inhibitor- based immunosuppression
2B
4. By improving glucose levels, PTA could have beneficial effects on underlying 
diabetic nephropathy in the long term
2B
C.3 – “In suitable PTA recipients, does PTA extend 
longevity or improve quality of life compared to 
current medical therapies?”
1. Patients with diabetes and impaired hypoglycemia awareness or diabetes 
and autonomic neuropathy have a high mortality risk and indirect evidence 
suggests that this group has improved longevity after PTA
NG
2. Overall PTA recipients have improved quality of life compared to patients 
remaining on the wait list
NG
C.4 – “After the first post- transplant year, is PTA 
superior to current medical therapies for 
metabolic control?”
Successful PTA provides normal or near normal glucose levels and therefore is 
superior to current medical therapies for hypoglycemia and hyperglycemia
2B
C.5 – “Is PTA superior to current medical therapies in 
the course of chronic complications of diabetes?”
Indirect evidence suggests that successful PTA could improve the long- term 
course of most chronic diabetes complications
NG
C.6 – “Is PTA superior to current medical therapies in 
the course of diabetic retinopathy?”
Depending on initial severity of diabetic retinopathy, successful PTA may 
contribute to stabilization or improvement of diabetic retinopathy
2B
C.7 – “Is PTA superior to current medical therapies in 
the course of diabetic nephropathy?”
Depending on the severity of diabetic nephropathy, successful PTA may slow 
progression of diabetic nephropathy. These beneficial effects may be offset 
by calcineurin inhibitor- related nephrotoxicity
NG
C.8 – “Is PTA superior to current medical therapies in 
the course of diabetic neuropathy?”
Depending on severity of diabetic neuropathy, evidence suggests that 
successful PTA slows the progression of diabetic neuropathy when 
compared to current medical therapies
2C
C.9 – “Is PTA superior to current medical therapies in 
the course of cardiovascular disease?”
Insufficient evidence is available to determine whether PTA slows progression 
of cardiovascular disease
NG
Abbreviations: NG, not graded; PTA, pancreas transplantation alone.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12  |   AJT BOGGI et al.
in 2012.96 Since then, only few additional cases (<20) were reported 
worldwide.97,98 All procedures were successful, but the generalizabil-
ity of these results remains to be established due to both selection 
biases and small sample size. The larger experience with robotic renal 
transplantation,99,100 as well as with other complex intra- abdominal 
procedures requiring vascular anastomoses,101,102 shows that ro-
botic assistance permits pancreas transplantation. Justification for 
the pursuit of further experience with robotic pancreas transplanta-
tion includes the possibility of minimizing the incidence and severity 
of local complications, such as perigraft fluid collections and surgical 
site infections, and potentially expediting postoperative recovery. 
Based on this background, experts could only conclude that robotic 
pancreas transplantation is feasible.
5.5  |  Expert panel recommendations— 
pancreas donation
5.5.1  |  Donor characteristics
In general, the use of donors not fulfilling ideal criteria was con-
sidered acceptable provided that the accumulation of additional 
risk factors and long ischemic times was avoided. In detail, in the 
setting of donation after brainstem death (DBD), experts did not 
recommend against the use of donors aged >40 years,103– 108 pedi-
atric donors,109– 113 and donors with a BMI > 30 kg/m2.114– 116 In the 
discussion, experts underscored that the use of pediatric donors of 
low body weight (<15 kg) may increase the risk of technical failure, 
while a BMI < 35 kg/m2 reduces the impact of obesity. In the setting 
of donation after circulatory death (DCD), the use of young con-
trolled DCD donors was not considered a contraindication to pan-
creas transplantation, as evidence showed that when donor age is 
<40 years, results are good irrespective of donor source (i.e., DCD 
or DBD).117– 124
5.5.2  |  Preservation solutions
The comparative value of different preservation solutions was ex-
tensively debated due to concerns on outcomes with increasing 
preservation times. When grafts are preserved for <12 h, experts 
agreed that University of Wisconsin (UW) and Celsior solutions 
are equally safe and effective. This recommendation was mostly 
supported by two single center prospective and randomized stud-
ies.125,126 On the contrary, UW was deemed to be superior to 
histidine- tryptophan- ketoglutarate (HTK) because of the descrip-
tion of higher rates of acute pancreatitis with HTK127 and concerns 
on suitability of this preservation solution with increasing preserva-
tion times. However, in the discussion, experts acknowledged that 
HTK can also be employed if preservation time does not exceed 
10 h and when using low perfusion volumes.128– 131 Finally, no con-
clusion could be drawn on Institut Georges Lopez- 1 (IGL- 1) solution, 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16  |   AJT BOGGI et al.
5.5.3  |  Procurement technique
Because of lack of comparative studies, experts could not decide 
about which procurement technique should be preferred (i.e., quick 
en- bloc or conventional technique). Reported results suggest that 
both techniques can be used based on individual preference and ex-
perience, with a preference for quick en- bloc techniques in hemody-
namically unstable donors.135– 137
5.5.4  |  Local versus imported grafts
Imported grafts were not considered to be associated with inferior 
outcomes when compared to local grafts, provided that a proficient 
team performed the procurement and that cold preservation times 
were acceptably short.138,139 The use of imported grafts increases 
costs and, despite efforts, is associated with longer preservation 
times that entail higher peak levels of pancreatic enzymes. Finally, re-
sults of available studies could have been influenced by several biases 
such as selective reporting (i.e., lack of intention- to- treat design), and 
use of different procurement techniques and preservation solutions.
5.5.5  |  Preservation time
Ideally, pancreatic grafts should be preserved for <12 h.140,141 
Preservation times up to 24 h can still be accepted. Beyond this time 
limit, acceptance of a pancreatic graft for transplantation is based 
on individual circumstances, such as specific recipient needs. As 
for other recommendations, accumulation of risk factors should be 
avoided.
5.5.6  |  Machine perfusion
No recommendation was drawn on the use of machine perfusion 
because of lack of clinical studies.142– 144
5.6  |  Expert panel recommendations— pancreas 
graft allocation
5.6.1  |  AB0- incompatible pancreas transplantation
AB0- incompatible pancreas transplantation was not considered 
an option for standard recipients of both SPK and solitary pan-
creas transplantations. Concerns about AB0- incompatible SPK 
transplantation are justified by the extremely low number of re-
ported cases145,146 that include an episode of humoral rejection, 
eventually rescued with eculizumab,145 and by the lack of com-
parisons with AB0- compatible SPK transplants. Concerns about 
AB0- incompatible solitary pancreas transplantations are strongly 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































18  |   AJT BOGGI et al.
pancreas transplantation should be considered investigational and 
should be performed only under urgent conditions or in clinical trials.
5.6.2  |  Positive crossmatch
In general, a positive crossmatch contraindicates pancreas transplan-
tation. Limited evidence shows that pretransplant B cell crossmatch 
positivity does not affect patient and pancreas graft survival, but is 
associated with higher rates of antibody- mediated rejection.147,148 
Few solitary pancreas transplants were performed despite a positive 
crossmatch with good outcomes.149,150
5.6.3  |  Donor- specific antibodies
Detection of DSAs up to an MFI level <5000 may not be an ab-
solute contraindication to pancreas transplantation if T and B cell 
crossmatch is negative. These recommendations are mostly sup-
ported by the lack of specific evidence showing the impact of 
pretransplant DSA on transplant outcomes. However, these rec-
ommendations may be subject to clinical and methodological limi-
tations, as detection of de novo DSA was associated with worse 
outcomes,150– 154 and MFI values are method dependent and hence 
center specific.
5.6.4  |  HLA mismatching
Reduced HLA mismatching was not specifically recommended in ei-
ther SPK or solitary pancreas transplantation. These recommenda-
tions are supported by evidence showing that in either transplant 
categories, reduced HLA mismatching decreases the incidence of 
acute rejection episodes and detection of de novo DSA, but does not 
improve overall results.155– 159 Additionally, matching for some HLA 
alleles, such as DR3, is associated with increased risk of autoimmune 
recurrence of diabetes.160
5.6.5  |  Preferential allocations of renal grafts
Renal grafts should be preferentially allocated to SPK recipients be-
cause of improved results with simultaneous vs. sequential trans-
plantation, practical implications in organization of multi- organ 
procurement, and a more evident survival advantage of kidney 
transplantation in diabetic vs. nondiabetic patients.33,34,37,53– 61
Preferential graft allocation to SPK could not be recommended 
in case of competition with highly sensitized recipients of a kidney 
alone transplantation with a negative crossmatch, because of lack 
of supporting evidence showing which transplant candidate could 
benefit most from that specific renal graft.64
Similarly, there is no evidence supporting priority for kidney 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    |  23AJTBOGGI et al.
transplantation and recipients of other simultaneous transplants 
(i.e., liver- kidney, heart- kidney, and lung- kidney).65 Finally, there is 
also no evidence to prioritize graft allocation for SPK transplantation 
based on the type of diabetes (i.e., type 1 vs. type 2) or recipient age 
(< vs. >50 years).
5.7  |  Expert panel recommendations— 
recipient selection
5.7.1  |  Native renal function in PTA recipients
Baseline renal function is considered key to reduce the risk of 
accelerated graft loss in PTA recipients function.73– 75 In patients 
with normal (eGFR ≥ 90 ml/min/1.73 m2) or mildly decreased 
(eGFR 60– 89 ml/min/1.73 m2) renal function and proteinuria 
(without nephrotic syndrome), experts recommended that the 
benefits of insulin independence should be balanced against the 
potential risk of worsening of nephropathy. Despite few studies 
have addressed this issue, this recipient population does not seem 
to be exposed to an undue risk of renal failure after PTA.161– 164 
The same recommendation was released for patients with the 
same level of renal function and nephrotic syndrome. However, 
this recommendation could not be graded as it was supported 
only by anecdotal cases.165
5.7.2  |  Impact of PTA on the course of chronic 
complications
In general, PTA improves the course of chronic complica-
tions of diabetes as compared to current medical thera-
pies,76,77,79,80,164,166,167 so that patients with evolving chronic 
complications could be considered for PTA before severe renal 
damage has occurred.
5.7.3  |  Selection of PAK recipients
In potential PAK recipients, a creatinine clearance ≤45 ml/min 
was not considered an absolute contraindication to sequential 
pancreas transplantation. Few and conflicting data exist on the 
prognostic implication of pre- PAK creatinine clearance using 
45 ml/min as a cutoff. In a retrospective and multicenter study, 
a pre- PAK eGFR ≤ 45 ml/min was associated with an increased 
probability of kidney graft failure.66 On the other hand, in an-
other retrospective study, eGFR significantly increased 3 months 
after grafting in patients with pretransplant eGFR ≤45 ml/min.168
In a retrospective and multicenter study reporting on PAK trans-
plant, history of renal rejection was associated with increased risk 
of posttransplant mortality, renal graft failure, and pancreas graft 
failure.66 However, experts did not recommend against PAK trans-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    |  25AJTBOGGI et al.
that HLA matching is optimized and DSA are avoided, because of 
lack of clear evidence discouraging sequential pancreas transplanta-
tion in these recipients.
Regarding the timing of sequential pancreas transplantation, 
experts did not contraindicate early PAK transplant (i.e., <6 months 
from kidney transplant) and underscored that results are im-
proved if PAK transplant is performed within 1 year after kidney 
transplantation.66,169,170
5.7.4  |  Preemptive SPK
Experts acknowledged that preemptive SPK transplant is associated 
with improved outcomes when compared to SPK transplant performed 
in patients undergoing dialysis. Indeed, several retrospective studies, 
including registry analysis, show that preemptive SPK transplantation 
is associated with improved outcomes when compared to SPK trans-
plantation performed in patients undergoing dialysis. Time on dialysis 
also has a negative prognostic impact in SPK recipients.59,171– 174
5.7.5  |  Other risk factors relevant to 
recipient selection
Obese patients may face a higher rate of early complications when 
compared to nonobese recipients175– 179 but obesity alone is not a con-
traindication to SPK transplant, considering that good results were 
reported.116 Discussion highlighted also the importance of under-
weight (BMI < 18.5 kg/m2), as a risk factor of long- term mortality.116
History of amputation and coronary heart disease were both 
considered risk factors for inferior results, but neither was deemed 
an absolute contraindication to SPK transplantation. Advanced ath-
erosclerotic peripheral arterial disease, including the need for limb 
amputation in diabetic patients, is associated with increased mortal-
ity.180 The association of advanced atherosclerotic peripheral arterial 
disease with end- stage renal failure increases the risk of mortality.181 
In general, pre- SPK limb amputation predicts inferior transplant out-
comes as it portends higher cardiovascular risk.182 Similarly, pretrans-
plant history of coronary artery disease increases the risk of major 
adverse cardiovascular events after transplantation.183,184 However, 
coronary artery disease is not a major risk factor for mortality if med-
ically treated and revascularized according to standard guidelines.185 
Discussion highlighted the importance of assessment of coronary 
artery disease in all patients undergoing pancreas transplantation.
5.8  |  Expert panel recommendations— 
surgical techniques
5.8.1  |  Exocrine drainage
Several studies, including three with a prospective design, have 
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pancreas transplantation. Bladder drainage, when compared to en-
teric drainage, does not increase immediate surgical complications 
but is associated with higher rates of late reintervention (mostly for 
enteric conversion).186– 206
Only one study clearly showed a higher rate of surgical complica-
tions in bladder- drained transplants (41% vs. 26%; p = .04).186 Need 
for enteric conversion was not considered a surgical complication 
in these studies, and was reported to occur in up to 20% of recipi-
ents.190 Two recent long- term studies reported that >40% of patients 
with bladder drainage require enteric conversion at some point in 
time.197,207 Additionally, bladder drainage increased the rate of meta-
bolic and urologic complications,188,198,208– 216 and did not improve im-
munologic outcome of either SPK187,190- 192,196- 198,205,206,208,214,217,218 
or solitary pancreas transplantations.70,171,219
Duodeno- duodenostomy (vs. duodeno- jejunostomy) was not 
considered to clearly increase the overall rate of surgical com-
plications after pancreas transplantation, despite higher rates of 
bleeding.220– 225 Additionally, duodeno- duodenostomy was not as-
sociated with improved immunologic outcomes, because of easier 
graft surveillance (endoscopic biopsy) with earlier diagnosis of rejec-
tion,222– 224 as reported in a study.221 Indeed, duodenal biopsy alone 
may not be sufficient to rule out rejection, as suggested by both ex-
perimental226 and clinical studies.227,228
5.8.2  |  Venous drainage
No study demonstrated that portal venous drainage increases 
surgical risk187,229– 235 but, on the other hand, no study showed 
either an immunologic,199,207,208,229,236 or a metabolic advantage
.233,234,237– 244
5.8.3  |  Graft placement
Regarding final graft position, intraperitoneal graft placement (vs. 
retroperitoneal graft placement) was not associated with higher 
incidence of surgical complications because of lack of compara-
tive studies.224,225,245,246 The hypothesis that retroperitoneal graft 
placement facilitates percutaneous graft biopsy remains to be 
proven.
5.9  |  Expert panel recommendations— 
immunosuppression
5.9.1  |  Steroids
The use of steroids remains prevalent in maintenance protocols 
after pancreas transplantation.40 Despite heterogeneity in back-
ground immunosuppressive regimens complicating interpretation of 
data, steroid avoidance is feasible in a good proportion of pancreas 
transplant recipients and does not result in inferior results when 
compared to steroid maintenance.247– 252 Early steroid withdrawal is 
also feasible.253– 258 Steroids avoidance, if maintained long term, is 
associated with improved metabolic profile.257,259– 262
5.9.2  |  Induction therapy
The use of induction therapy, typically in the form of depleting an-
tibodies, is prevalent across all pancreas transplant categories.40 
Two randomized controlled trials showed that induction therapy is 
associated with improved immunologic outcomes when compared 
to a policy of no induction therapy.263,264 However, there is no clear 
evidence that induction with depleting vs. nondepleting antibodies 
results in improved immunologic outcomes in patients at low immu-
nologic risk (i.e., PRA < 10%).
Regarding safety, induction with depleting antibodies is associ-
ated with cytokine release syndrome requiring premedication and 
with an increased incidence of early posttransplant infections, in 
particular CMV viremia, when compared with a policy of use of non-
depleting antibodies or no induction therapy.40,263,265 Despite expe-
rience in renal transplantation showing that induction therapy with 
depleting antibodies is associated with increased rates of oncologic 
complications,266 there is no clear evidence that this applies to recip-
ients of pancreas transplantation.
In comparison to a policy of no induction, experts agreed that 
induction is associated with improved immunologic outcomes, and 
that induction with depleting antibodies is associated with increased 
rates and severity of early posttransplant infections (that do not 
result in inferior patient and graft survival) without evidence of in-
creased risk of oncologic complications.
In comparison to a policy of induction with nondepleting anti-
bodies in recipients at low immunologic risk (i.e., PRA < 10%), experts 
agreed that induction with depleting antibodies vs. induction with 
nondepleting antibodies does not improve immunologic outcomes 
and is associated with increased rates and severity of early post-
transplant infections (that do not result in inferior patient and graft 
survival). However, there is no clear evidence that induction with 
depleting antibodies increases the risk of oncologic complications.
5.9.3  |  CNI- free regimen
The main rationale for CNI- free immunosuppression is to avoid the 
side effects of CNI- based immunosuppression. However, long- term 
data on outcomes of patients maintained on CNI- free regimens after 
pancreas transplantation are lacking. Short- term data are sparse and 
suggest that this strategy is associated with inferior immunologic 
outcomes without a clear reduction in drug- related toxicity.252,262
Relatively more data are available for protocols of immuno-
suppression minimization and delayed withdrawal of CNI. In se-
lected patients at low immunologic risk, these strategies may 
achieve immunologic results similar to CNI- based immunosuppres-
sion.256,274,275,276 Results of a prospective and randomized trial 
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published after this Consensus Conference showed that CNI- free 
immunosuppression based on sirolimus achieved good patient and 
graft survival rates, but at the price of high drop- out rate (68%) and 
increased incidence of de novo DSA anti- class II HLA antigens at 
12 months (19% vs. 2%). Additionally, due to high surgical compli-
cation rates, introduction of sirolimus was delayed until posttrans-
plant month 3.277 A phase 2 multicenter open- label randomized 
trial, that was also published after the Consensus Conference, 
compared the outcomes of SPK recipients treated with an immu-
nosuppressive regimen including tacrolimus vs. a protocol using 
low- dose CNI plus costimulation blockade (belatacept) with in-
tended CNI withdrawal. In both arms, patients received induction 
therapy with rabbit thymoglobulin, while steroids were rapidly 
withdrawn, and maintenance therapy included also mycophenolate 
sodium or mycophenolate mofetil. CNI withdrawal was associated 
with increased rates of pancreas rejection, despite similar rates of 
kidney rejection. The study was terminated after randomization of 
43 of 60 planned patients. The authors concluded that costimula-
tion blockade with belatacept did not provide sufficient immuno-
suppression to reliably prevent rejection of the pancreas in SPK 
transplants undergoing CNI withdrawal. Low- dose CNI used in 
conjunction with belatacept was sufficient to prevent rejection of 
both kidney and pancreas, while increasing the incidence of oppor-
tunistic infections.278
In comparison to CNI- based immunosuppression, experts 
agreed that CNI- free immunosuppression is associated with inferior 
immunologic outcomes without evidence of reduced drug- related 
toxicity.
5.9.4  |  CNI- based regimen
The use of tacrolimus is prevalent in all categories of pancreas trans-
plantation.40 One multicenter, prospective, and randomized study 
showed that tacrolimus achieved superior immunologic results when 
compared to cyclosporine in SPK transplant recipients, although the 
high incidence of pancreas allograft thrombosis recorded in the cy-
closporine arm may constitute a major bias of this study.267 A sin-
gle center, prospective, and randomized study did not confirm the 
superiority of tacrolimus over cyclosporine in SPK transplant re-
cipients.268 Basically, the introduction of tacrolimus corresponded 
to clinical success in solitary pancreas transplantation and com-
parison with historical series using cyclosporine showed improved 
results.72,269
Reported experience with the use of once- a- day tacrolimus for-
mulation in pancreas transplantation is limited. Data are available 
only for SPK transplantation and show that once- a- day tacrolimus 
formulation is associated with excellent patient and graft survival, 
and that patients can be safely converted from standard tacrolimus 
to long- acting tacrolimus.270– 273
In comparison with cyclosporine, experts agreed that the use of 
tacrolimus is prevalent in all pancreas transplant categories and is as-
sociated with superior immunologic outcomes. No conclusion could 
be drawn on the comparative efficacy of once- a- day vs. twice- a- day 
tacrolimus formulations due to lack of supporting data.
5.9.5  |  Mycophenolate formulations
The use of mycophenolate formulations is clearly prevalent in pan-
creas transplantation.40 A prospective, multicenter, randomized, 
open- label study comparing mycophenolate mofetil to azathioprine, 
in the setting of OKT3 induction and steroid/cyclosporine mainte-
nance, did not demonstrate the superiority of mycophenolate mofetil 
in SPK transplantation.279 An additional prospective and randomized 
study conducted at a single center showed that mycophenolate 
mofetil significantly decreased the incidence of biopsy- proven acute 
rejection in SPK transplantation.280 A review showed that the use 
of mycophenolate mofetil in combination with a CNI and steroids, 
after induction treatment, was associated with a 40% reduction in 
the incidence of acute rejection at 1 year after pancreas transplan-
tation.281 Retrospective studies have shown that mycophenolate 
mofetil compared to azathioprine improves immunologic outcome 
of pancreas transplantation when used in combination with either 
tacrolimus or cyclosporine, but at the price of more gastrointestinal 
side effects that frequently require dose reduction.269,282,283
In comparison to azathioprine, experts agreed that mycopheno-
late formulations improve immunologic outcomes but are associated 
with more gastrointestinal side effects.
5.9.6  |  m- TOR inhibitors
An analysis of all pancreas transplants included in the UNOS data-
base from 1987 to 2016 showed that the use of m- TOR inhibitors 
when compared to immunosuppressive protocols without m- TOR 
inhibitors was associated with improved allograft survival and pa-
tient survival up to 10 years after transplantation.284 However, 
there is no evidence that the use of m- TOR inhibitors improves im-
munologic outcomes of pancreas transplantation when compared 
to mycophenolate formulations. The results of a multicenter, pro-
spective, and randomized study comparing sirolimus and mycophe-
nolate mofetil in SPK recipients were never published. Preliminary 
data from this trial showed that sirolimus was potentially associ-
ated with improved immunologic outcomes285 but at the price of 
a higher incidence of surgical complications (i.e., delayed wound 
healing, lymphocele, and incisional hernia) and hyperlipidemia.286 
Two retrospective studies showed that the results of sirolimus 
and mycophenolate mofetil were similar when used in combina-
tion with tacrolimus.254,287 A single center, randomized, and pro-
spective study with 10- year follow- up showed significantly better 
rates of rejection with sirolimus,288 although allograft and patient 
survival rates were similar.
There are only few data on comparative efficacy of m- TOR- 
based immunosuppression vs. CNI- based immunosuppression in 
pancreas transplantation when these drugs are used as primary 
    |  29AJTBOGGI et al.
immunosuppressants. In general, CNI- free immunosuppression in 
pancreas transplantation is associated with inferior immunologic 
outcomes.251,266 In selected patients at low immunologic risk, m- TOR 
inhibitors may allow CNI minimization, while maintaining satisfac-
tory immunologic results.252,275,276 Data from a recently published 
prospective and randomized study showed that immediate use of 
sirolimus after SPK transplantation, in the context of CNI- free immu-
nosuppression, is associated with an increased rate of surgical com-
plications.277 Additionally, the use of m- TOR inhibitors in the setting 
of CNI- free immunosuppression could increase the formation of 
DSA.289 This issue is not fully addressed in the literature. Reported 
outcomes range from no effect,290 to increased development on 
nondonor- specific HLA antibodies, with immediate evidence of 
worse graft outcome,291 and to an increased incidence of de novo 
DSA anti- class II HLA agents at 1 year after transplantation.277
In comparison with mycophenolate formulations, and in the 
context of limited evidence, experts acknowledged that the use 
of m- TOR inhibitors is not clearly associated with an immunologic 
advantage. Additionally, when both drugs are used as primary im-
munosuppressants, experts agreed that the use of m- TOR inhibitors 
vs. mycophenolate formulations is associated with specific and less 
well- tolerated side effects.
In comparison with CNI- based immunosuppression, experts 
agreed that the use of m- TOR inhibitors is not associated with an 
immunologic advantage. Lack of specific evidence did not allow ex-
perts to define if m- TOR- based immunosuppression is associated 
with more side effects.
5.9.7  |  Summary of immunosuppression
State of the art immunosuppressive regimen for all categories of 
pancreas transplantation consists in induction with depleting anti-
body and maintenance with tacrolimus, mycophenolate, and ster-
oids. Early steroid withdrawal is feasible and may result in improved 
metabolic parameters in the long- term period.
The avoidance of CNI is associated with inferior immunologic 
outcomes without clear evidence of reduced toxicity. Concerns 
about early outcomes of CNI- free immunosuppression are an addi-
tional and major clinical issue.
Mycophenolate formulations improve immunologic outcomes 
when compared to azathioprine but are associated with high rates of 
gastrointestinal side effects.
m- TOR- based immunosuppression is not associated with an 
immunologic advantage when compared to CNI- based immu-
nosuppression. The use of m- TOR inhibitors vs. mycophenolate 
formulations could be associated with improved immunologic out-
comes but carry more side effects, especially if used as primary 
immunosuppressants. Immediate posttransplant use of m- TOR 
inhibitors is associated with high rates of surgical complications, 
making delayed introduction preferable. In the context of CNI- free 
regimens, m- TOR- based immunosuppression may increase the de-
velopment of DSA.
5.10  |  Expert panel recommendations— 
postoperative prophylaxis
5.10.1  |  Antithrombotic prophylaxis
Vascular thrombosis is the leading cause of early graft loss in pan-
creas transplantation.292 The high incidence of vascular thrombosis 
in pancreas grafts is explained by multiple factors such as the hyper-
coagulable state of diabetic patients,292,293 increased donor age,294 
donor obesity,292 cerebrovascular cause of donor death,294 low mi-
crocirculatory blood flow of the pancreas allograft,295 need for back 
table vascular reconstructions,294 preservation injury,292 long pres-
ervation times,296 occurrence of graft pancreatitis,292,294 endothelial 
damage promoted by high CNI levels,293 and the disproportion in 
size between the large vascular pedicles and the small pancreatic 
branches following splenectomy and enterectomy.292 Finally, vascu-
lar allograft thrombosis may also be caused, or promoted, by missed 
rejection.297
Experts recommended that per protocol antithrombotic prophy-
laxis should be given to all pancreas transplant recipients, although 
there is not enough evidence to define which prophylaxis protocol 
should be used.293,298– 305
Regarding deep venous thrombosis, recipients of both SPK and 
solitary pancreas transplantation are at increased risk for deep ve-
nous thrombosis and pulmonary embolism. However, no study is 
available to compare a policy of no antithrombotic prophylaxis vs. a 
policy of per protocol antithrombotic prophylaxis in pancreas trans-
plant recipients for the prevention of deep venous thrombosis and 
pulmonary embolism. There are also no studies comparing differ-
ent anticoagulation prophylaxis protocols.293,298– 305 Experts did not 
recommend antithrombotic prophylaxis for the prevention of deep 
venous thrombosis in SPK recipients, due to lack of supporting evi-
dence, while recommended antithrombotic prophylaxis in recipients 
of solitary pancreas transplants, taking into consideration also the 
higher risk of graft thrombosis in this recipient categories. Due to 
lack of evidence, decision on type and degree of antithrombotic pro-
phylaxis could not be specified.
A further question was about the use of anticoagulation vs. 
anti- aggregation antiplatelet therapy. Many pancreas transplant 
recipients are already under chronic anti- aggregant therapy at the 
time of transplantation due to underlying cardiovascular disease 
or cardiovascular risk factors. Therefore, postoperative anticoagu-
lant prophylaxis typically occurs in the setting of preexisting anti- 
aggregation. Because of lack of comparative studies, experts could 
not indicate a preference for a specific strategy.
5.10.2  |  Antiviral prophylaxis
Recipients of pancreas transplantation are at high risk for virus ac-
tivation or infection due to the frequent use of induction therapy 
with T- cell depleting antibodies, in particular when steroids are also 
used.40 Most of the available literature focuses on cytomegalovirus 
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infection as infection with other viruses occurs less frequently. 
Published studies251,263,306– 312 and a Consensus Conference313 on 
the management of cytomegalovirus in solid organ transplanta-
tion show that antiviral prophylaxis should be provided to pancreas 
transplant recipients. The type of antiviral drug, as well as duration 
of prophylaxis, can be tailored based on donor/recipient matching 
for cytomegalovirus serological status. When anti- cytomegalovirus 
medications are not administered, prophylaxis against herpes sim-
plex virus and varicella- zoster virus should be considered.
Based on this background, experts recommended implementa-
tion of antiviral prophylaxis in most pancreas transplant recipients.
Regarding the use of prophylaxis or preemptive cytomegalovirus 
therapy, experts recommended prophylaxis in seronegative recipi-
ents receiving grafts from CMV- seropositive donors.306,313 In other 
donor/recipient pairs, either strategies were considered acceptable.
5.10.3  |  Antimycotic prophylaxis
Pancreas transplantation is associated with a risk of fungal infec-
tion. Fungal infections are associated with reduced patient and 
graft survival. Available literature does not provide clear evidence 
that fungal prophylaxis should be used in all pancreas transplant 
recipients. A selective policy of antifungal prophylaxis in patients 
at higher risk for invasive fungal infection is justified. Most centers 
use a protocolized short duration, systemic antifungal prophylaxis 
strategy.312,314– 321 Experts recommended the use of antimycotic 
prophylaxis, as per center protocol, to mitigate the risk of invasive 
fungal infections.
5.10.4  |  Antimicrobial prophylaxis
Pancreas transplantation is associated with a high risk of bacterial 
infection. Antibacterial prophylaxis is largely prescribed following 
pancreas transplantation and is associated with a reduced inci-
dence and severity of posttransplant bacterial infections. Debate 
remains concerning the ideal combination of antibiotics to use 
for prophylaxis as well as duration of prophylaxis.322– 328 Experts 
recommended the use of antimicrobial prophylaxis, as per center 
protocol.
5.10.5  |  Vaccination
This consensus was held before the SARS- CoV- 2 pandemic. 
Therefore, any recommendations on vaccination against SARS- 
CoV- 2 have not been included.
While vaccination strategies have not been studied specifically 
in the setting of pancreas transplantation, evidence derived from 
experience in transplantation of other solid organs329 supports a 
role for multiple vaccinations, based on individual needs, to reduce 
the incidence of late post- transplant infections. Therefore, experts 
recommended vaccinations in pancreas transplant recipients, based 
on general consensus guidelines.
5.11  |  Expert panel recommendations— 
immunology
5.11.1  |  DSA monitoring
The role of DSA is emerging as an important factor in immunologi-
cal graft failure. Regarding a policy of per protocol evaluation of 
DSA, there is no specific study that has compared the immunologic 
outcome of pancreas transplant recipients with vs. without DSA 
monitoring. However, despite conflicting data,154,330 several stud-
ies showed an association between de novo DSA and increased 
rate of rejection episodes/poorer graft survival in pancreas 
transplantation.150– 153 Experts recommended DSA monitoring after 
pancreas transplantation.
5.11.2  |  Per protocol pancreas graft biopsy
There is no specific evidence supporting protocol biopsies in SPK 
transplant recipients, but in solitary pancreas grafts protocol bi-
opsy improved immunologic outcomes.331,332 Considering also 
that concordance between renal and pancreatic biopsy is not 
complete,333– 335 experts concluded that per protocol biopsy in SPK 
transplant recipients is center specific and may help in immunologic 
surveillance.
In solitary pancreas transplantation, few studies showed 
that protocol pancreas biopsy may improve immunologic out-
come.331,332 Pancreatic biopsy should be preferred over duodenal 
biopsy, when feasible, because concordance between pancreatic 
and duodenal biopsies is limited.228 Experts concluded that use of 
protocol biopsy in solitary pancreas transplants is center specific. 
It may help in graft surveillance, especially if combined with DSA 
monitoring.
5.11.3  |  Treatment of first rejection episodes
No prospective and randomized study has compared steroids vs. T- 
cell depleting antibody as a treatment of first rejection episodes in 
pancreas transplantation. Most authors treat first, or mild, rejection 
episodes with steroid pulses. Treatment with T cell depleting anti-
bodies is typically reserved to patients with recurrent, or moderate/
severe, rejection episodes.333,336– 339 A recent study found that out-
come of first rejection episodes is not improved by administration of 
T- cell depleting antibodies when mild, but is improved when moder-
ate or severe.340 Experts recommended the use of steroids for treat-
ment of clinically diagnosed rejection episodes or biopsy- proven 
grade 1 rejection. T- cell depleting antibodies can be used for higher 
rejection grades or based on clinical history and immunologic data.
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5.11.4  |  Treatment of second rejection episodes
There is basically no evidence in the literature supporting how a sec-
ond rejection episode should be treated in recipients of solitary pan-
creas transplants. Experts recommended that treatment of second 
rejection episodes should be individualized. T- cell depleting antibod-
ies should be used in most patients.
5.11.5  |  Treatment of antibody- mediated rejection
The importance of antibody- mediated rejection in pancreas trans-
plantation is becoming increasingly evident. However, the defini-
tion of antibody- mediated rejection has changed over time. Earlier 
studies defined antibody- mediated rejection as the combined pres-
ence of DSAs, graft dysfunction, and C4d positivity on histology 
slides.341,342 These criteria were incorporated in the Banff schema 
for grading of pancreas allograft rejection published in 2008.343 
However, DSAs can be detected in the absence of rejection, graft 
dysfunction can occur without rejection and, as shown in kidney 
transplantation, C4d positivity may not be sufficient to establish a 
diagnosis of antibody- mediated rejection.344 Updated Banff grading 
schema replaced graft dysfunction with histologic evidence of acute 
tissue injury.344,345
Currently available treatment strategies are basically derived 
from renal transplantation, and there are no comparative studies 
that specifically address the efficacy of these protocols in pancreas 
transplantation. Treatment options include the use of plasma ex-
change and intravenous immunoglobulins either alone342,346 or in 
combination with rituximab.341,347,349 A management algorithm was 
proposed by Redfield et al in 2015.348
Because of lack of specific data, experts could not draw a spe-
cific recommendation, and suggested that treatment of antibody- 
mediated rejection in pancreas transplantation can be individualized 
based on clinical history and immunologic data.
5.11.6  |  Surveillance for autoimmune 
recurrence of diabetes
After the first description by Sutherland, Goetz, and Sibley in 
1989,350 autoimmune recurrence of diabetes is increasingly recog-
nized as an important cause of graft loss. While the presence of au-
toantibodies before pancreas transplantation has no impact on graft 
outcome, major autoantibody changes (serum conversion, spreading 
from one to multiple autoantibodies, or titer increase) are predictive 
of subsequent loss of graft function.160,351– 353 More recently, the 
recurrence of autoreactive CD4 T cells has been described in both 
recipients’ blood and pancreas grafts.354 Monitoring of autoreactive 
CD4 T cells, in combination with autoantibodies and biopsies, was 
described in three SPK recipients with autoimmune recurrence.355 
Current status of autoimmune monitoring in pancreas transplanta-
tion is described in several reviews.356,357
Experts recommended per protocol assay of autoantibodies re-
lated to autoimmune recurrence of type 1 diabetes. In patients with 
rising antibodies and/or impaired pancreas allograft function (in the 
absence of other obvious reasons of graft injury), experts recom-
mended also the use of pancreas allograft biopsy to establish the 
diagnosis of autoimmune recurrence of diabetes.
5.12  |  Expert panel recommendations— follow- up
5.12.1  |  Effects of pancreas transplantation on 
diabetic retinopathy
The impact of SPK transplantation on diabetic retinopathy is 
controversial.78,358– 363 In the most recent studies, diabetic retin-
opathy is stabilized/improved after successful SPK transplanta-
tion.78,358,359 It should be noted that diabetic retinopathy is often 
severe in these patients, which makes reversal of the retinal damage 
unlikely. Results are better if accurate retinal examination is per-
formed pre- SPK transplantation and appropriate ocular treatment 
ensured. Experts acknowledged that successful SPK transplantation 
may contribute to stabilization/improvement of diabetic retinopathy 
depending on retinopathy stage, and recommended that patients 
are monitored closely by an ophthalmologist for progression in ad-
vanced retinopathy stages.
Few studies have addressed the effects of PTA on retinopathy 
(including one in comparison with insulin therapy and one in com-
parison with failed PTA). Generally, successful PTA is associated with 
improved stabilization of advanced retinopathy and increased lesion 
reversal in nonproliferative retinopathy. One study reports the de-
celeration of retinal damage early after PTA, with potential stabili-
zation over time.26,78,80 Experts acknowledged that successful PTA 
contributes to stabilization/improvement of diabetic retinopathy.
5.12.2  |  Effects of pancreas transplantation on 
diabetic nephropathy
Several studies have compared the effects of SPK transplantation 
on the survival of the transplanted kidney in comparison with the 
survival of renal alone grafts from deceased or living donors. The 
superiority of SPK vs. deceased donor renal transplantation is well 
established, whereas that vs. live donor renal transplantation is still 
uncertain. A few studies suggest that the function of the grafted 
kidney is better in SPK transplant than in recipients of live donor 
renal transplantation.364– 366 Experts acknowledged that successful 
SPK transplantation prevents development/occurrence of diabetic 
nephropathy in the kidney graft.
Several studies have evaluated the effects of PTA on the native 
kidneys, which can be damaged by immunosuppressive drug nephro-
toxicity. Over the years, due to better titration of immunosuppres-
sion and selection of recipients, the rate of chronic kidney disease in 
PTA recipients has progressively diminished. Currently, the 10- year 
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cumulative incidence of post- PTA chronic kidney disease ranges 
from 10 to 30% when the pre- PTA eGFR is >60 ml/min/1.73 m2, 
with some authors suggesting a threshold of eGFR pre- PTA of 70 ml/
min/1.73 m2. Less information is available on the role of associated 
albuminuria. Some data show that in patients with a functioning 
PTA and not evolving toward chronic kidney disease, the decrease in 
eGFR over time is similar to that observed in the general T1D popu-
lation.26,27,76 Experts acknowledged that functioning PTA improves 
the evolution of diabetic nephropathy, but underscored as these ben-
eficial effects may be sometimes offset by CNI- related nephropathy.
5.12.3  |  Effects of pancreas transplantation on 
diabetic neuropathy
Several studies, including prospective analyses, have evaluated 
the effects of SPK transplantation on somatic and autonomic 
neuropathy, also in comparison with kidney transplant alone and 
standard insulin therapy. Overall, evidence suggests that SPK 
transplantation improves symptoms of somatic neuropathy, pa-
rameters of peripheral nerve function, and autonomic nervous 
system cardiorespiratory tests, possibly also due to rescue from 
uremia. Insufficient data are available on the impact of SPK trans-
plantation on advanced autonomic nervous system alterations, 
such as gastroparesis and neurogenic bladder.79,367– 372 Experts 
acknowledged that SPK transplantation has beneficial effects on 
mild to moderate neuropathy.
Scant information is available on the effects of PTA on dia-
betic neuropathy. Published data suggest some improvements in 
nerve conduction velocity, autonomic function, and epinephrine 
response.28,166 Experts acknowledged that successful PTA may im-
prove the course of diabetic neuropathy.
5.12.4  |  Effects of pancreas transplantation on 
cardiovascular system
A few studies evaluated the effects of SPK transplantation on the 
cardiovascular system, also in comparison with kidney transplant 
alone. SPK transplantation has been reported to be associated 
with lower rate of cardiovascular death and reduced progression 
of carotid and lower limb arterial damage.52,182,373– 377 Experts ac-
knowledged that SPK transplantation has beneficial effects on the 
cardiovascular system, including lower rate of cardiovascular death 
compared with either dialysis or kidney alone transplantation.
Limited data are available on the effects of PTA on the cardiovas-
cular system, and mainly from a single group. PTA can lead to early 
and persistent reduction of a few cardiovascular risk factors (total 
and LDL cholesterol, blood pressure) and improved cardiac mor-
phology and function (including diastolic parameters) as assessed by 
ultrasound evaluation.29,167,375– 377 Experts concluded that evidence 
available on the effects of PTA on the cardiovascular system is not 
sufficient to draw a final conclusion.
5.12.5  |  Effects of pancreas transplantation on 
quality of life
Several studies have evaluated the effects of SPK transplanta-
tion on recipients’ quality of life, mostly in comparison with kidney 
graft alone recipients or diabetic patients on dialysis. Consistently, 
successful grafting is associated with improved scores in multiple 
domains.21– 25 Experts acknowledged that successful SPK transplan-
tation is associated with improved quality of life.
Little information is available on the effects of PTA on recipients’ 
quality of life. Available data suggest enhanced quality of life after 
PTA.30– 32 Experts acknowledged that PTA improves recipient qual-
ity of life compared to patients on waiting list.
5.13  |  Research agenda
Opportunities for research are presented as proposed actions for 
each recommendation in Tables 4- 12. In general, the level of evi-
dence was quite low demonstrating that well- designed studies as 
well as meta- analyses are greatly needed for many topics.
Additional studies are more urgently needed for volume- 
outcome relationship, pancreas allocation strategies, efficacy of 
IGL- 1 solution (vs. UW solution), clinical role of machine perfu-
sion, induction with depleting antibodies vs. induction without 
depleting antibodies in patients at low immunologic risk, pancreas 
transplantation in patients with type 2 diabetes, long- term results 
of preemptive SPK (vs. SPK in patients in dialysis), comparison of 
different anticoagulation prophylaxis regimens (including com-
parison between anticoagulation and anti- aggregation protocols), 
strategies for immunologic surveillance, treatment of rejection 
episodes (in particular, treatment of second rejection episodes 
and treatment of antibody- mediated rejections), effects of PTA on 
cardiovascular system, and effects of PTA on recipients’ quality 
of life.
Multicenter studies are particularly needed.
5.14  |  Limitations
As already reported while describing the methods of this consensus 
conference,42 the main limitation of our collaborative effort was the 
need to review 50+ years of literature and consequently to extract 
data from several hundreds of articles. This extraordinary effort has 
intrinsic limitations and carries the risk of unintentional selection 
bias. Despite the creation of several dedicated teams for literature 
review, sharing and presentation of results of literature search, and 
online and in- person discussion of each statement, we acknowl-
edge that some articles could have been missed. Additionally, 
Ovid/Medline was not included in the systematic reviews, and 
only data from full peer- reviewed manuscripts were considered. 
Consequently, we might have been missed additional information 
from these data sources.
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Some of the data examined and discussed to reach the consen-
sus may have been influenced by local practice as well as geograph-
ical and institutional variations. As most studies were provided by 
the United States and Europe, the applicability of these guidelines in 
other countries may require adaptations to local practice, legislative 
framework, organizational needs, epidemiology of organ donation, 
and other geographical/cultural variations.
Despite our effort to include all major transplant centers, and 
to specifically involve all physicians with known competence in 
pancreas transplantation, some prominent centers and influen-
tial colleagues may have not been invited or could not participate. 
However, having reached consensus among a large group of interna-
tionally recognized experts ensures balanced and competent assess-
ment of available evidence.
5.15  |  Conclusions
In conclusion, we have reported on 49 jury deliberations and 
110 experts’ recommendations, that we believe can be used to 
support and improve practice of pancreas transplantation world-
wide. The main message from this consensus conference is that 
both SPK and PTA have the potential to improve patient sur-
vival in the long- term period, while all types of pancreas trans-
plantation dramatically improve the quality of life of recipients. 
These advantages clearly appear to outweigh potential disad-
vantages, thus encouraging further implementation of pancreas 
transplantation.
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